ArticleJournal of molecular histology2026
TMEM130 promoter hypermethylation predicts tumor cell migration in cervical cancer.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cervical cancer represents a prevalent malignancy affecting women globally, DNA methylation serves as a crucial epigenetic modification influencing disease prognosis through the regulation of gene expression. The aim of this study is to elucidate the potential impact of TMEM130 promoter methylation on its transcriptional activity and to explore the functional role of TMEM130 in the migration of cervical cancer cells. Clinical data and gene expression profiles from The Cancer Genome Atlas (TCGA) were analyzed to assess the correlation between TMEM130 expression and patient overall survival. Transcriptional levels of TMEM130 in cervical cancer cell lines and clinical specimens were quantified via qRT-PCR, revealing significant downregulation relative to normal controls, consistent with the TCGA findings. Reduced TMEM130 expression was associated with poorer overall survival. Bisulfite sequencing PCR (BSP) confirmed hypermethylation of the TMEM130 promoter in tumor tissues and treatment with a methyltransferase inhibitor restored TMEM130 expression. Functional assays, including Transwell migration and Western blot analyses following TMEM130 plasmid transfection, demonstrated that TMEM130 overexpression suppressed migratory capabilities in cervical cancer cells. These findings suggested that in cervical cancer TMEM130 might act as a tumor suppressor, with promoter hypermethylation contributing to its downregulation, promising its potential as a biomarker for disease progression.
Indexed as
Identifiers
41718894What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.